vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $13.8M, roughly 1.6× CB Financial Services, Inc.). On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 19.9%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CBFV vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $21.9M |
| Net Profit | — | $1.6M |
| Gross Margin | — | — |
| Operating Margin | 38.1% | 9.0% |
| Net Margin | — | 7.2% |
| Revenue YoY | 19.9% | 1292.3% |
| Net Profit YoY | — | 116.7% |
| EPS (diluted) | $0.90 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $21.9M | ||
| Q3 25 | $2.4M | $2.1M | ||
| Q2 25 | $13.5M | $3.0M | ||
| Q1 25 | $12.1M | $421.0K | ||
| Q4 24 | $13.2M | $1.6M | ||
| Q3 24 | $12.7M | $3.3M | ||
| Q2 24 | $12.2M | $2.7M | ||
| Q1 24 | $13.5M | $1.7M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | $-5.7M | $-7.4M | ||
| Q2 25 | $3.9M | $-8.5M | ||
| Q1 25 | $1.9M | $-12.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.2M | $-8.7M | ||
| Q2 24 | $2.6M | $-10.2M | ||
| Q1 24 | $4.2M | $-12.3M |
| Q4 25 | 38.1% | 9.0% | ||
| Q3 25 | -289.8% | -353.4% | ||
| Q2 25 | 35.0% | -292.3% | ||
| Q1 25 | 19.3% | -2921.4% | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 31.2% | -264.2% | ||
| Q2 24 | 26.4% | -390.6% | ||
| Q1 24 | 37.9% | -737.8% |
| Q4 25 | — | 7.2% | ||
| Q3 25 | -235.2% | -346.6% | ||
| Q2 25 | 29.3% | -287.1% | ||
| Q1 25 | 15.8% | -2911.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.3% | -259.6% | ||
| Q2 24 | 21.8% | -382.7% | ||
| Q1 24 | 31.1% | -719.1% |
| Q4 25 | $0.90 | $0.05 | ||
| Q3 25 | $-1.07 | $-0.07 | ||
| Q2 25 | $0.74 | $-0.09 | ||
| Q1 25 | $0.35 | $-0.17 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.60 | $-0.17 | ||
| Q2 24 | $0.51 | $-0.20 | ||
| Q1 24 | $0.82 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $157.5M | $26.4M |
| Total Assets | $1.5B | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $27.1M | ||
| Q3 25 | $55.9M | $11.7M | ||
| Q2 25 | $64.5M | $27.5M | ||
| Q1 25 | $61.3M | $13.1M | ||
| Q4 24 | $49.6M | $22.5M | ||
| Q3 24 | $147.3M | $32.4M | ||
| Q2 24 | $142.6M | $30.0M | ||
| Q1 24 | $73.7M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $157.5M | $26.4M | ||
| Q3 25 | $152.5M | $13.2M | ||
| Q2 25 | $148.4M | $18.2M | ||
| Q1 25 | $148.3M | $6.6M | ||
| Q4 24 | $147.4M | $17.5M | ||
| Q3 24 | $149.1M | $25.4M | ||
| Q2 24 | $142.9M | $21.6M | ||
| Q1 24 | $141.6M | $30.0M |
| Q4 25 | $1.5B | $42.2M | ||
| Q3 25 | $1.5B | $31.6M | ||
| Q2 25 | $1.5B | $40.7M | ||
| Q1 25 | $1.5B | $22.3M | ||
| Q4 24 | $1.5B | $32.2M | ||
| Q3 24 | $1.6B | $44.8M | ||
| Q2 24 | $1.6B | $42.3M | ||
| Q1 24 | $1.5B | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-1.1M |
| Free Cash FlowOCF − Capex | $17.2M | — |
| FCF MarginFCF / Revenue | 124.1% | — |
| Capex IntensityCapex / Revenue | 4.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $-1.1M | ||
| Q3 25 | $4.6M | $-9.0M | ||
| Q2 25 | $4.1M | $-3.4M | ||
| Q1 25 | $4.0M | $-8.2M | ||
| Q4 24 | $6.8M | $-36.3M | ||
| Q3 24 | $3.1M | $-7.5M | ||
| Q2 24 | $-1.2M | $-10.0M | ||
| Q1 24 | $3.3M | $-9.8M |
| Q4 25 | $17.2M | — | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $3.9M | $-3.4M | ||
| Q1 25 | $3.9M | $-8.3M | ||
| Q4 24 | $3.4M | $-36.4M | ||
| Q3 24 | $2.2M | $-7.5M | ||
| Q2 24 | $-2.4M | $-10.0M | ||
| Q1 24 | $2.3M | $-9.8M |
| Q4 25 | 124.1% | — | ||
| Q3 25 | 186.5% | — | ||
| Q2 25 | 28.8% | -116.5% | ||
| Q1 25 | 32.5% | -1976.7% | ||
| Q4 24 | 26.0% | -2309.3% | ||
| Q3 24 | 17.4% | -225.7% | ||
| Q2 24 | -19.6% | -376.2% | ||
| Q1 24 | 17.0% | -573.0% |
| Q4 25 | 4.7% | 0.0% | ||
| Q3 25 | 4.3% | 0.0% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 0.8% | 35.6% | ||
| Q4 24 | 25.1% | 4.2% | ||
| Q3 24 | 6.7% | 0.0% | ||
| Q2 24 | 10.0% | 0.4% | ||
| Q1 24 | 7.2% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
